Immuno-Oncology | Specialty

The immuno-oncology condition center is a comprehensive resource for clinical news and expert insights on immuno-oncology. Read more at OncLive.

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

June 3rd 2025

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

First-Line Nivolumab Plus Ipilimumab Does Not Boost OS in Cisplatin-Ineligible Unresectable Urothelial Carcinoma

June 1st 2025

Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.

Indirect Comparisons Shows Relatlimab/Nivolumab Has Comparable Outcomes to Ipilimumab/Nivolumab in Advanced Melanoma

June 1st 2025

The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.

Sintilimab/Chidamide Plus P-GemOx Shows Antitumor Activity in Treatment-Naive, Early-Stage Natural Killer/T-Cell Lymphoma

June 1st 2025

Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer

June 1st 2025

Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.

Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma

June 1st 2025

The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.

Dr Matrana on the Persisting Need For Validated Biomarkers to Guide Treatment Selection in RCC

May 31st 2025

Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.

ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC

May 31st 2025

Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30th 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI

May 30th 2025

Ivonescimab plus chemotherapy improved PFS vs chemotherapy alone in second- and later-line EGFR-mutated non–small cell lung cancer.

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

May 15th 2025

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

FDA Approval of Penpulimab Expands Treatment Options in Recurrent/Metastatic Non-Keratinizing NPC

May 15th 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC

May 13th 2025

Belrestotug plus dostarlimab did not improve PFS vs dostarlimab monotherapy in PD-L1–high NSCLC, supporting the termination of belrestotug development.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025

May 1st 2025

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Invikafusp Alfa Generates Clinical Activity in Checkpoint Inhibitor–Resistant Solid Tumors

April 29th 2025

Invikafusp alfa was active in unresectable, locally advanced or metastatic solid tumors resistant to immune checkpoint inhibitors.

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC

April 27th 2025

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC

April 26th 2025

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.